Evidence map›Paper›PMID 42685702›Full record

ArticleCell reports. Medicine2026

Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.

Devra J Olson, Bernard A Liu, Patrick Younan, Gabriele Blahnik-Fagan, R Greg Stacey, John Gosink, Katie Snead, Elena Tenn, Kelly Hensley, Disha Sahetya and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Devra J OlsonPfizer, Inc., Bothell, WA 98021, USA.
Bernard A LiuPfizer, Inc., Bothell, WA 98021, USA.
Patrick YounanSeagen, Inc., Bothell, WA 98021, USA.
Gabriele Blahnik-FaganPfizer, Inc., Bothell, WA 98021, USA.
R Greg StaceyPfizer, Inc., Bothell, WA 98021, USA.
John GosinkPfizer, Inc., Bothell, WA 98021, USA.
Katie SneadPfizer, Inc., Bothell, WA 98021, USA.
Elena TennSeagen, Inc., Bothell, WA 98021, USA.
Kelly HensleyPfizer, Inc., Bothell, WA 98021, USA.
Disha SahetyaPfizer, Inc., Bothell, WA 98021, USA.
Albina NesterovaPfizer, Inc., Bothell, WA 98021, USA.
Margo ZavalSeagen, Inc., Bothell, WA 98021, USA.
Anthony CaoSeagen, Inc., Bothell, WA 98021, USA.
Christine O'DayPfizer, Inc., Bothell, WA 98021, USA.
Ryan A HeiserPfizer, Inc., Bothell, WA 98021, USA.
Timothy S LewisSeagen, Inc., Bothell, WA 98021, USA.
Shyra J GardaiSeagen, Inc., Bothell, WA 98021, USA.
Taisuke NakazawaAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Masashi ShimazakiAstellas Research Institute of America LLC, Northbrook, IL 60062, USA.
Christopher CarosinoPfizer, Inc., Bothell, WA 98021, USA.
Gregory L SzetoPfizer, Inc., Bothell, WA 98021, USA.
Sharsti SandallPfizer, Inc., Bothell, WA 98021, USA. Electronic address: sharsti.sandall@pfizer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enfortumab vedotin is a Nectin-4-directed antibody-drug conjugate designed to deliver the microtubule-disrupting agent monomethyl auristatin E (MMAE) to tumor cells. Using preclinical models of urothelial cancer (UC), we expand the understanding of the multifaceted mechanism of action for enfortumab vedotin that includes direct cytotoxicity on Nectin-4-positive tumor cells, indirect bystander effect on neighboring Nectin-4-negative tumor cells, and MMAE-mediated induction of immunogenic cell death (ICD) and associated increase in activated immune cells in the tumor microenvironment. Importantly, vaccination with enfortumab vedotin-treated tumor cells results in protection against tumor rechallenge in mice, consistent with antitumor immunity. MMAE-mediated ICD induction modulates the tumor microenvironment in a complementary manner to immune checkpoint inhibition. Accordingly, enfortumab vedotin plus PD-1 inhibitor shows enhanced antitumor activity in vivo. These preclinical findings provide mechanistic hypotheses that may be relevant to the improved clinical outcomes observed for enfortumab vedotin plus pembrolizumab relative to chemotherapy.

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsImmune Checkpoint InhibitorsImmunoconjugatesImmunogenic Cell DeathProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorFemaleHumansMiceNectinsOligopeptidesTumor MicroenvironmentUrinary Bladder NeoplasmsAntibodies, MonoclonalAntineoplastic Agentsenfortumab vedotinImmune Checkpoint InhibitorsImmunoconjugatesmonomethyl auristatin ENECTIN4 protein, humanNectinsOligopeptidesProgrammed Cell Death 1 ReceptorADCantibody-drug conjugatebladder cancerbystander-activityenfortumab vedotinEVICDimmunogenic cell deathmicrotubulesMMAEnectin-4PD-1 inhibitorpembrolizumab

Identifiers

PMID42685702
PMCPMC13589495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.